Back to search results

Phase 2 Volrustomig for Non-Small Cell Lung Cancer

This study is testing a new drug called volrustomig in combination with other cancer medications like carboplatin, pemetrexed, ramucirumab, and paclitaxel for people with non-small cell lung cancer. Researchers want to see how safe these combinations are, how well your body handles them, and if they can shrink tumors. You might be able to join if you are 18 or older, have a good general health status (ECOG performance status of 0 or 1), a life expectancy of at least 12 weeks, and adequate organ function. The study aims to enroll 180 participants, but its current recruitment status is unclear.

Study design
This is an open-label, multi-center Phase 2 study, meaning both you and your doctors will know which treatments you are receiving. It is a platform study with two substudies, and participants will be randomized into different treatment arms.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events and serious adverse events for up to 2 years and 10 months. Tumor response will also be measured for up to 2 years and 10 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06448754

Volrustomig Priming Regimens Exploratory Phase II Platform Study

Recruiting
PHASE2Ages 18+InterventionalTreatment
AstraZeneca
~180 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:VolrustomigCarboplatinPemetrexedRamucirumabPaclitaxel

At a glance

Recruiting sites
57 of 77 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over From screening (Days -28 to Day -1) up to 2 year 10 months
+1 more outcome measured

Conditions

Non-small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell CarcinomaSolid Neoplasm

Where it's being run

77 sites across 20 states
Spain10
Italy9
Georgia6
Portugal6
China5
France5
Greece5
Switzerland5

Who to contact

AstraZeneca Clinical Study Information Center
[email protected]
1-877-240-9479
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
Life expectancy greater than or equal to (\>=) 12 weeks.
Adequate organ and bone marrow function.
Body weight greater than (\>) 35 kilograms (kg) at screening and at randomization.
Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
At least one measurable lesion not previously irradiated that can be accurately measured at baseline as \>= 10 millimeter (mm) in the longest diameter.

Exclusion

Spinal cord compression.
History of primary active immunodeficiency.
Active or prior documented autoimmune or inflammatory disorders.
Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (\>) 12 months from end of last therapy.

What this trial measures

  • Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)From screening (Days -28 to Day -1) up to 2 year 10 months

    The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed.

  • Confirmed Objective Response rate (ORR)Up to 2 year 10 months

    ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).